1. Home
  2. IPGP vs APLS Comparison

IPGP vs APLS Comparison

Compare IPGP & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IPG Photonics Corporation

IPGP

IPG Photonics Corporation

HOLD

Current Price

$101.67

Market Cap

4.4B

Sector

Technology

ML Signal

HOLD

Logo Apellis Pharmaceuticals Inc.

APLS

Apellis Pharmaceuticals Inc.

SELL

Current Price

$41.05

Market Cap

5.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
IPGP
APLS
Founded
1990
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.2B
IPO Year
2000
2015

Fundamental Metrics

Financial Performance
Metric
IPGP
APLS
Price
$101.67
$41.05
Analyst Decision
Strong Buy
Hold
Analyst Count
5
21
Target Price
$131.40
$33.59
AVG Volume (30 Days)
586.5K
6.7M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
117.85
112.50
EPS
0.04
0.15
Revenue
$1,003,777,000.00
$1,003,782,000.00
Revenue This Year
$12.18
N/A
Revenue Next Year
$8.44
$18.19
P/E Ratio
$2,625.50
$273.60
Revenue Growth
2.73
28.46
52 Week Low
$63.33
$16.61
52 Week High
$155.82
$41.14

Technical Indicators

Market Signals
Indicator
IPGP
APLS
Relative Strength Index (RSI) 41.07 84.57
Support Level $76.61 $19.29
Resistance Level $129.39 $41.14
Average True Range (ATR) 5.71 0.06
MACD -0.85 -0.65
Stochastic Oscillator 39.04 58.33

Price Performance

Historical Comparison
IPGP
APLS

About IPGP IPG Photonics Corporation

IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, laser and non-laser systems, fiber amplifiers, diode lasers, and related optical components. Its products are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. The company sells its products globally to original equipment manufacturers (OEMs), system integrators, and end users. Additionally, it manufactures complementary products used with its lasers, including optical delivery cables, fiber couplers, beam switches, optical processing heads, in-line sensors, and chillers. Geographically, the company generates maximum revenue from North America, followed by China, Japan, Germany, and other markets.

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Share on Social Networks: